| Dr Iana Gueorguieva, MD | |
|
39450 W 12 Mile Rd, Novi, MI 48377-3600 | |
| (248) 344-4147 | |
| Not Available |
| Full Name | Dr Iana Gueorguieva |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Gastroenterology |
| Location | 39450 W 12 Mile Rd, Novi, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750813234 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 4301119146 (Michigan) | Primary |
| Entity Name | Henry Ford Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144801 PECOS PAC ID: 0547178311 Enrollment ID: O20031105000139 |
News Archive
Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body.
Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.
Up to 30 percent of people who receive organ transplants will develop diabetes, but researchers are unsure why. Although doctors typically blame immunosuppressive drugs that transplant recipients take to prevent organ rejection, it's unclear why some people develop the lifelong disorder, while others do not.
Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.
FerroKin BioSciences, a biotechnology company developing a new therapy for the treatment of iron overload, today announced the closing of a $12 million financing. Participants in the financing include current investors Burrill & Company, Celgene Corporation, Clarus Ventures and MP Healthcare Venture Management, Inc., with Healthcap Ventures of Stockholm participating as a new investor.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Iana Gueorguieva, MD 39450 W 12 Mile Rd, Department Of Gastroenterology, Novi, MI 48377-3600 Ph: (248) 344-4147 | Dr Iana Gueorguieva, MD 39450 W 12 Mile Rd, Novi, MI 48377-3600 Ph: (248) 344-4147 |
News Archive
Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body.
Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.
Up to 30 percent of people who receive organ transplants will develop diabetes, but researchers are unsure why. Although doctors typically blame immunosuppressive drugs that transplant recipients take to prevent organ rejection, it's unclear why some people develop the lifelong disorder, while others do not.
Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.
FerroKin BioSciences, a biotechnology company developing a new therapy for the treatment of iron overload, today announced the closing of a $12 million financing. Participants in the financing include current investors Burrill & Company, Celgene Corporation, Clarus Ventures and MP Healthcare Venture Management, Inc., with Healthcap Ventures of Stockholm participating as a new investor.
› Verified 6 days ago
Dr. James Barry Lesser, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 44000 W 12 Mile Rd, Suite 103, Novi, MI 48377 Phone: 248-347-8290 Fax: 248-305-6845 | |
Usha M Singhi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 505, Novi, MI 48374 Phone: 248-465-4163 Fax: 248-465-4434 | |
Stafford Adrian Preston, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 44000 West Twelve Mile Road, Suite 200, Novi, MI 48377 Phone: 248-347-8191 Fax: 248-347-8110 | |
Dr. Serge Alexander Sorser, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 350, Novi, MI 48374 Phone: 248-662-4110 Fax: 248-662-4120 | |
Mohammad Alhaji, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 39475 Lewis Dr Ste 200, Novi, MI 48377 Phone: 248-471-0675 Fax: 248-254-3874 | |
Dr. Lawrence Livernois Joseph Macdonald, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 44000 W 12 Mile Rd, Suite 113, Novi, MI 48377 Phone: 248-465-9253 Fax: 248-465-9285 | |
Raid Hashim Fadhil Al-khersan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 505, Novi, MI 48374 Phone: 248-465-4163 Fax: 248-662-4411 |